Video

The Design Behind the Development of a Novel-Risk Prediction Model in Lung Cancer Screening

Joshua Roth, PhD, assistant member, Fred Hutchinson Cancer Research Center, discusses the design of a novel risk-prediction algorithm in the context of screening patients for lung cancer.

Joshua Roth, PhD, assistant member, Fred Hutchinson Cancer Research Center, discusses the design of a novel risk-prediction algorithm in the context of screening patients for lung cancer.

The database analysis used SEER data, which provided detailed information regarding patients with early stage non-small cell lung cancer (NSCLC). Looking at different factors, researchers investigated the likelihood of death within 30 days of surgery.

This data was then fed back to the screening process and can be a part of the conversation between the patient and physician as they discuss treatment options, explains Roth.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD